Hiroaki Goto

Hiroaki Goto

Auto-generated profile, based on publicly available information

Hiroaki Goto

Division of Hematology/Oncology Kanagawa Children's Medical Center Yokohama Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2021 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
DFDoz François
Doz François
CTCornelis M van Tilburg
Cornelis M van Tilburg
BGBirgit Geoerger
Birgit Geoerger
MHMartin Højgaard
Martin Højgaard
IØIngrid Øra
Ingrid Øra
SPSebastien Perreault
Sebastien Perreault
Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive cancer. The aim of this study was to evaluate the efficacy and safety of larotrectinib in patients with TRK fusion-positive primary central nervous system (CNS) tumors. Patients with TRK fusion-positive primary CNS tumors from two clinical trials (NCT02637687, NCT02576431) were identified. The primary endpoint was investigator-assessed objective response rate (ORR). As of July 2020, 33 patients with TRK fusion-positive CNS tumors were identified (median age: 8.9 years; range: 1.3–79.0). The most common histologies were high-grade glioma (HGG; n = 19) and low-grade glioma (LGG; n = 8). ORR was 30% (95% confidence interval [CI]: 16–49) for all patients. The 24-week disease control rate was 73% (95% CI: 54–87). Twenty-three of 28 patients (82%) with measurable disease had tumor shrinkage. The 12-month rates for duration of response, progression-free survival, and overall survival were 75% (95% CI: 45–100), 56% (95% CI: 38–74), and 85% (95% CI: 71–99), respectively. Median time to response was 1.9 months (range 1.0–3.8 months). Duration of treatment ranged from 1.2–31.3+ months. Treatment-related adverse events were reported for 20 patients, with grade 3–4 in 3 patients. No new safety signals were identified. In patients with TRK fusion-positive CNS tumors, larotrectinib demonstrated rapid and durable responses, high disease control rate, and a favorable safety profile.

17 August 2023 in Blood
Verified
Journal Article
Closed access
PDF file
YCYunchao Chang
Yunchao Chang
FKFatemeh Keramatnia
Fatemeh Keramatnia
PGPankaj S. Ghate
Pankaj S. Ghate
GNGisele Nishiguchi
Gisele Nishiguchi
QGQingsong Gao
Qingsong Gao
CMCharles G Mullighan
Charles G Mullighan
Advancing cure rates for high-risk acute lymphoblastic leukemia (ALL) has been limited by the lack of agents that effectively kill leukemic cells, sparing normal hematopoietic tissue. Molecular glues direct the ubiquitin ligase cellular machinery to target neosubstrates for protein degradation. We developed a novel cereblon modulator, SJ6986, that exhibits potent and selective degradation of GSPT1 and GSPT2 and cytotoxic activity against childhood cancer cell lines. Here, we report in vitro and in vivo testing of the activity of this agent in a panel of ALL cell lines and xenografts. SJ6986 exhibited similar cytotoxicity to the previously described GSPT1 degrader CC-90009 in a panel of leukemia cell lines in vitro, resulting in apoptosis and perturbation of cell cycle progression. SJ6986 was more effective than CC-90009 in suppressing leukemic cell growth in vivo, partly attributable to favorable pharmacokinetic properties, and did not significantly impair differentiation of human CD34+ cells ex vivo. Genome-wide CRISPR/Cas9 screening of ALL cell lines treated with SJ6986 confirmed that components of the CRL4CRBN complex, associated adaptors, regulators, and effectors were integral in mediating the action of SJ6986. SJ6986 is a potent, selective, orally bioavailable GSPT1/2 degrader that shows broad antileukemic activity and has potential for clinical development.

2 December 2015 in Pediatrics International
Verified
Journal Article
Closed access
PDF file
HGHiroaki Goto
Hiroaki Goto

29 January 2020 in Pediatrics International
Verified
Journal Article
Open access
AHAkiko Hayashi
Akiko Hayashi
EIEiko Ito
Eiko Ito
MOMotoko Omura
Motoko Omura
NANoriko Aida
Noriko Aida
MTMio Tanaka
Mio Tanaka
HGHiroaki Goto
Hiroaki Goto
Background: Overall survival (OS) of patients with diffuse intrinsic pontine glioma (DIPG) is poor, with radiation therapy (RT) the only intervention that transiently delays tumor progression. Hypofractionated RT and re‐irradiation at first progression have gained popularity in improving the quality of life of such patients.Methods: We performed a retrospective review of children with DIPG treated at Kanagawa Children's Medical Center from 2000 to 2018.Results: A total of 24 cases were reviewed. Median age at diagnosis was 6.3 years (1.6–14.0). Twenty patients received RT only once. Thirteen patients received conventionally fractionated RT, and seven patients received hypofractionated RT as up‐front RT. Severe toxicities were not observed in patients who received hypofractionated RT. Median OS and time to progression were similar between conventionally fractionated and hypofractionated RT groups.(9.7 [95% confidence interval(CI): 7.1‐11.2] versus 11.0[95% CI: 5.2‐13.6] months, P = 0.60; 4.2[95% CI: 1.8‐8.3] versus 7.1 [95% CI:4.5‐8.7] months, P = 0.38). Four patients received re‐irradiation at first progression and all patients showed transient neurological improvement and survival more than a year after diagnosis. A 4‐year‐old boy was re‐irradiated 5‐and‐a‐half months after the first re‐irradiation; following transient neurological improvement. He survived a further 5 months.Conclusion: Hypofractionated RT for children with newly diagnosed DIPG is well tolerated and feasible from the viewpoint of reducing a patient's burden of treatment. Re‐irradiation at first progression is suggested to be beneficial.

4 February 2019 in Bone Marrow Transplantation
Verified
Journal Article
Open access
YOYasuhiro Okamoto
Yasuhiro Okamoto
KKKazuko Kudo
Kazuko Kudo
KTKen Tabuchi
Ken Tabuchi
DTDaisuke Tomizawa
Daisuke Tomizawa
TTTakashi Taga
Takashi Taga
HIHiroyuki Ishida
Hiroyuki Ishida
Allogeneic hematopoietic stem cell transplantation (HSCT) can be used to treat children with refractory acute myeloid leukemia (AML). This retrospective analysis aimed to describe the outcomes and risk factors in such children. Data were collected through the nation-wide registry program in Japan. A total of 417 AML (median age: 13 years) patients 20 years or younger at HSCT, between January 2001 and December 2015, were included. A total of 314 patients died, and the median follow-up duration of the survivors was 1052 days. The most frequent cause of death was leukemia progression (58%). The 3-year overall survival (OS) rate was 23% (95% confidence interval [CI]: 19-28%). Chronic GVHD was associated with improved 3-year OS (47%, 95% CI, 36-57%, hazard ratio: 0.603, p = 0.001). Low performance status, presence of more than 25% of marrow blasts, presence of blasts in the blood at transplantation, FAB (other than M1 or M2), male donors, and number of transplantations ≥ 2 were adverse pre-HSCT variables. Patients with 0, 1-2, 3-4, 5, and 6-7 pre-HSCT variables had 3-year OS rates of 52%, 32%, 19%, 8, and 0%, respectively. Our findings may help experts decide if HSCT should be performed in such cases.

6 March 2020 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
HGHiroaki Goto
Hiroaki Goto
YYYuki Yoshino
Yuki Yoshino
MIMieko Ito
Mieko Ito
JNJunichi Nagai
Junichi Nagai
TKTadashi Kumamoto
Tadashi Kumamoto
SGShoko Goto
Shoko Goto